Drug Profile
Letermovir - Merck & Co
Alternative Names: AIC-001; AIC-090027; AIC-246; BAY-73-6327; MK-8228; PREVYMIS; PREVYMIS™-BMT; PREVYMIS™-SOTLatest Information Update: 25 Jan 2024
Price :
$50
*
At a glance
- Originator Bayer
- Developer Dana-Farber Cancer Institute; Merck & Co
- Class Acetates; Antivirals; Fluorobenzenes; Phenyl ethers; Piperazines; Quinazolines; Small molecules
- Mechanism of Action Terminase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cytomegalovirus infections
Most Recent Events
- 30 Nov 2023 Merck Sharp & Dohme in collaboration with National Institute of Allergy and Infectious Diseases completes a phase II ELICIT trial in Cytomegalovirus infections (In adults, In the elderly) in USA (PO) (NCT04840199)
- 17 Oct 2023 Committee for Medicinal Products for Human Use (CHMP) recommends approval for extending dosing for PREVYMIS from 100 days to 200 days following transplant in adult CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT) who are at risk for late cytomegalovirus (CMV) infections in EU
- 17 Oct 2023 Committee for Medicinal Products for Human Use (CHMP) recommends approval of letermovir for cytomegalovirus (CMV) infections in adult kidney transplant recipients at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-]) in EU